Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 6/20 | 0.47 |
| ▸ | PIK3CA | P42336 | 9/20 | 0.43 |
| ▸ | GPR142 | Q7Z601 | 2/20 | 0.38 |
| ▸ | ESR1 | P03372 | 1/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.38 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10070995 | 0.91 | RIPK1 (0.48) | RIPK1PIK3CAGPR142ESR1ESR2 | |
| SCHEMBL14023336 | 0.88 | RIPK1 (0.48) | RIPK1PIK3CAGPR142ESR1ESR2 | |
| SCHEMBL807151 | 0.86 | RIPK1 (0.47) | RIPK1PIK3CAGPR142ESR1ESR2 | |
| SCHEMBL10070490 | 0.85 | RIPK1 (0.44) | RIPK1PIK3CAGPR142 | |
| SCHEMBL10075222 | 0.82 | RIPK1 (0.46) | RIPK1PIK3CAESR2 | |
| SCHEMBL10070492 | 0.81 | RYR2 (0.46) | RIPK1PIK3CAGPR142 | |
| SCHEMBL10074953 | 0.78 | RIPK1 (0.46) | RIPK1PIK3CAESR2 | |
| SCHEMBL806685 | 0.77 | CYP3A4 (0.43) | RIPK1PIK3CAP2RY1EPHX2 | |
| SCHEMBL14480703 | 0.75 | PIK3CA (0.51) | RIPK1PIK3CAGPR142EPHX2 | |
| SCHEMBL807044 | 0.74 | RYR2 (0.58) | RIPK1GPR142ESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012019071-A1 | METHODS OF PREVENTING AND TREATING SARCOPENIA | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2012-02-09 | — | — | WO | disclosed |
| WO-2008144483-A2 | AGENTS FOR TREATING DISORDERS INVOLVING MODULATION OF RYANODINE RECEPTORS | ARMGO PHARMA, INC. (US) | 2008-11-27 | — | — | WO | disclosed |